GSK plc's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 ...

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Q1 2025 Earnings Call Transcript April 30, 2025 GSK plc beats earnings expectations. Reported EPS is $1.13, expectations were ...

Dr. Kate Knobil joins the biotech as it looks to combat a viral infection that can be dangerous to patients with the lung ...

Pharmaceutical firm Gilead has admitted paying hundreds of thousands of dollars in illegal kickbacks to US doctors between ...

Uncertainty continues to hang over the latest round of financial results and forecasts for companies both big and small as ...

European stocks closed higher on Wednesday, as investors pored through another slew of earnings and reacted to ...

GSK PLC closed 21.47% short of its 52-week high of £18.24, which the company reached on May 16th.

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

GSK PLC closed 22.73% below its 52-week high of £18.24, which the company reached on May 16th.

Hanwha, which bought the South Philly yard last year, wants to add waterfront land and may expand into South Jersey.